TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03732742

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TOF repair with trans-annular patch VS preservation of PV
Description: One group study

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TOF repair with trans-annular patch VS preservation of PV
Description: One group study
Study: NCT01374568

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sitagliptin
Description: sitagliptin 100mg daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 pill daily
Study: NCT03723018

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation
Description: 10 minutes a day of meditation, done on your own time.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation
Description: 10 minutes a day of meditation, done on your own time.
Study: NCT04910139

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soniflow System
Description: Treatment using acoustic vibrational headband worn circumferentially at the level of the forehead paired with a Smartphone App.
Study: NCT03968380

Intervention type: OTHER
Intervention: Population survey with biological and physical measurements.
Description: Individuals will be interviewed in their homes by trained interviewers. At a later date, in a location agreed with the study team, a sample of blood will be taken and we will measure fasting glucose, cholesterol level and creatinine. We will measure participants' height, weight, waist circumference and blood pressure. An Oral Glucose Tolerance Test (OGTT) will be performed on non-diabetic and/or non-pregnant participants.

Intervention type: OTHER
Intervention: Population survey with biological and physical measurements.
Description: Individuals will be interviewed in their homes by trained interviewers. At a later date, in a location agreed with the study team, a sample of blood will be taken and we will measure fasting glucose, cholesterol level and creatinine. We will measure participants' height, weight, waist circumference and blood pressure. An Oral Glucose Tolerance Test (OGTT) will be performed on non-diabetic and/or non-pregnant participants.
Study: NCT01971801

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 50,000 IU
Description: Capsule given by mouth once a week

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule given by mouth weekly
Study: NCT03296670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprostadil
Description: alprostadil,2ug, delivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients with CSFP

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nitroglycerin
Description: Nitroglycerin,200ug, delivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients with CSFP
Study: NCT02799147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Study: NCT02449551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volitinib
Description: Volitinib is an orally available, potent, selective, small molecule c-MET inhibitor. Volitinib 800 mg will be administered orally once a day for 21 days as one cycle.
Study: NCT03485599

Intervention type: DIAGNOSTIC_TEST
Intervention: ELIZA , Westron blot
Description: Blood sample will be taken then rapid test by ELIZA will be done if positive then confirmatory test by Westron blot will be done
Study: NCT00792285

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Automated Telephone Outreach with Speech Recognition
Description: Automated Telephone Outreach with Speech Recognition calls to health plan members to promote screening
Study: NCT02533024

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electromyography
Description: All subjects will have an EMG before, during and immediately after surgery.
Study: NCT00452777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BVT.115959

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03949153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab 10 MG/ML Intravenous Solution [OPDIVO]
Description: Single Nivolumab 240 mg infusion at D0

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: Cryotherapy using interventional radiology of metastatic lymphadenopathy at D1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab Injection
Description: In situ injection with ipilimumab at D2.
Study: NCT00324558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bemiparin
Description: subcutaneous administration (sc) of Bemiparin (3,500 UI/day) for 26 weeks, starting on the first day of chemotherapy (CT)
Study: NCT00457652

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: 7 day treatment rosuvastatin 20mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rosuvastatin
Description: 7 day treatment rosuvastatin 20mg
Study: NCT04618562

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Revival Active Program
Description: Program comprised of physical activities, group play, mind games, reasoning and discussion on sleeted topics, breath work and relaxation techniques, 60 minutes all together.
Study: NCT02690259

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sentinel node procedure
Description: Patients with Endometrial cancer undergo Sentinel node procedure using Indocyanine green
Study: NCT01559129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide (CC-4047)
Description: 1 mg orally every day for 52 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules taken orally once a day
Study: NCT00701857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Standard weekly dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Biweekly pemetrexed dose escalation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Weekly standard dose radiation therapy
Study: NCT03385590

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy-fiber-maize
Description: Two servings of soy-maize porridge fortified with soy fiber (1.3 g per serving) will be consumed by the children each day for a period of six months.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Maize
Description: Two servings of maize porridge will be consumed by the children each day for a period of six months.
Study: NCT00517400

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deep repetitive Transcranial Magnetic Stimulation (rTMS) real or sham

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deep repetitive Transcranial Magnetic Stimulation (rTMS) real or sham

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deep repetitive Transcranial Magnetic Stimulation (rTMS) real or sham
Study: NCT01555840

Intervention type: DEVICE
Group type: OTHER
Intervention: Magnetically Guided Capsule (MGCE)
Description: a) MGCE capsule The MGCE capsule is custom-made for observation of the stomach. It is 31 mm in length and 11 mm in diameter and equipped with two image sensors.~It contains a permanent magnet to enable magnetic guidance in the stomach by magnetic field. b) Guidance system The magnet guidance system is custom-made to guide the MGCE capsule inside the stomach. It has a footprint of 1m× 2m and generates a very low level magnetic fields. c) Conventional gastroscope
Study: NCT03800953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: The study treatment comprises two phases, the concurrent immune-chemoradiotherapy (Ave-PF-CRT) phase and the immune-chemotherapy (Ave-PF) phase. All the subjects will receive Avelumab at both phases.
Study: NCT00881062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proellex
Description: A single oral dose administered after at least a 10 hour fast
Study: NCT02535091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YKP3089
Description: see above
Study: NCT01834872

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amigo

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual ablation
Study: NCT05319912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1840 Enteric-coated Tablet
Description: ALXN1840 (60 milligrams) was administered orally as EC tablets at Hour 0 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1840 Enteric-coated Tablet
Description: ALXN1840 (60 milligrams) was administered orally as EC tablets at Hour 0 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1840 Enteric-coated Tablet
Description: ALXN1840 (60 milligrams) was administered orally as EC tablets at Hour 0 on Day 1.
Study: NCT02298972

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nurse support and selfmanagement intervention
Study: NCT02344316

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: Taken at 9 PM or 1 hour before bedtime, whichever is earlier
Study: NCT05319912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1840 Enteric-coated Tablet
Description: ALXN1840 (60 milligrams) was administered orally as EC tablets at Hour 0 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1840 Enteric-coated Tablet
Description: ALXN1840 (60 milligrams) was administered orally as EC tablets at Hour 0 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1840 Enteric-coated Tablet
Description: ALXN1840 (60 milligrams) was administered orally as EC tablets at Hour 0 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1840 Non-coated Capsule
Description: ALXN1840 (60 milligrams) was administered orally as non-coated capsules at Hour 0 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1840 Non-coated Capsule
Description: ALXN1840 (60 milligrams) was administered orally as non-coated capsules at Hour 0 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1840 Non-coated Capsule
Description: ALXN1840 (60 milligrams) was administered orally as non-coated capsules at Hour 0 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1840 Non-coated Capsule
Description: ALXN1840 (60 milligrams) was administered orally as non-coated capsules at Hour 0 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1840 Non-coated Capsule
Description: ALXN1840 (60 milligrams) was administered orally as non-coated capsules at Hour 0 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1840 Non-coated Capsule
Description: ALXN1840 (60 milligrams) was administered orally as non-coated capsules at Hour 0 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Omeprazole (20 milligrams) was administered orally as a delayed-release capsule in the morning of Days -5 to -1 and at Hour -1 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Omeprazole (20 milligrams) was administered orally as a delayed-release capsule in the morning of Days -5 to -1 and at Hour -1 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Omeprazole (20 milligrams) was administered orally as a delayed-release capsule in the morning of Days -5 to -1 and at Hour -1 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Omeprazole (20 milligrams) was administered orally as a delayed-release capsule in the morning of Days -5 to -1 and at Hour -1 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Omeprazole (20 milligrams) was administered orally as a delayed-release capsule in the morning of Days -5 to -1 and at Hour -1 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Omeprazole (20 milligrams) was administered orally as a delayed-release capsule in the morning of Days -5 to -1 and at Hour -1 on Day 1.
Study: NCT02798042

Intervention type: OTHER
Intervention: Urine Sample
Description: We plan to collect a urine sample during the pre-surgical visit.
Study: NCT04239677

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional crystalloid solution-based priming
Description: CPB circuit is also prepared with crystalloid solution-based priming in all participants (same as the RAP group). In this group (control group), CPB is initiated with antegrade priming (conventional priming).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Retrograde autologous priming
Description: CPB circuit is prepared with crystalloid solution-based priming in all participants. In RAP group, retrograde autologous priming is performed by displacing the crystalloid priming volume of arterial and venous lines via passive exsanguination of native blood prior to CPB initiation.
Study: NCT02344316

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo taken at 9 PM or 1 hour before bedtime, whichever is earlier
Study: NCT01280357

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monica AN24 (K101081)
Description: If not confident of Monica AN24 displayed data then remove Monica AN24 monitor and continue monitoring with Philips 50XM

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Philips 50XM
Description: If not confident of Monica AN24 displayed data then remove Monica AN24 monitor and continue monitoring with Philips 50XM
Study: NCT01505413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib 100 mg po qd daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m² with 150mL of normal saline intravenously infusion over 100min on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 100 mg/m2 with 500mL of 5DW intravenously a 2-hour infusion on D2
Study: NCT00975728

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alixir - Pomegranate, apple and Açai drink / Placebo
Description: 250 ml/day Alixir/Placebo for Group 2 for 8 weeks 500 ml/day Alixir/Placebo for Group 1 for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alixir - Pomegranate, apple and Açai drink / Placebo
Description: 250 ml/day Alixir/Placebo for Group 2 for 8 weeks 500 ml/day Alixir/Placebo for Group 1 for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alixir - Pomegranate, apple and Açai drink / Placebo
Description: 250 ml/day Alixir/Placebo for Group 2 for 8 weeks 500 ml/day Alixir/Placebo for Group 1 for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alixir - Pomegranate, apple and Açai drink / Placebo
Description: 250 ml/day Alixir/Placebo for Group 2 for 8 weeks 500 ml/day Alixir/Placebo for Group 1 for 8 weeks
Study: NCT06448962

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AD-2021
Description: PO, Once daily(QD), 8weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-2021
Description: PO, Once daily(QD), 8weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AD-2022
Description: PO, Once daily(QD), 8weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-2022
Description: PO, Once daily(QD), 8weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AD-2021 Placebo
Description: PO, Once daily(QD), 8weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AD-2022 Placebo
Description: PO, Once daily(QD), 8weeks
Study: NCT03940833

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCMA CAR-NK 92 cells
Description: The subject will be observed for any side effects during this time and all the adverse events will be recorded.
Study: NCT03620513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decongestant (oxymetazoline 0.05%)
Description: As described in arm/group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anesthesia (Lidocaine 15%)
Description: As described in arm/group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decongestants and Anesthesia (oxymetazoline and lidocaine)
Description: As described in arm/group
Study: NCT02818244

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fit Bit Blaze Heart Rate Monitoring Device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Garmin Forerunner 235 Heart Rate Monitoring Device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tom Tom Spark Cardio Heart Rate Monitoring Device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Apple Watch Heart Rate Monitoring Device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Scosche Rhythm + Heart Rate Monitor
Study: NCT03454126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB095
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB095
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB095
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB095
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB095
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB095
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB095
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB095
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB095
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB095
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB095
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as specified in the treatment arm.
Study: NCT03620513

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Spray of normal saline as premedication
Study: NCT03429101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poziotinib
Description: Poziotinib is a tablet for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-DM1
Description: T-DM1 (ado-trastuzumab emtansine) is a HER2-targeted therapy for I.V. administration.
Study: NCT03539094

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent fasting
Description: the subjects randomized to this group will do IF by restricting their diet and consuming few calories two days per week. During the days of fasting, subjects will be allowed to drink water, calorie-free beverages, and eat fresh, steamed or roasted non-starchy vegetables.
Study: NCT01662544

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oxygen delivery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen delivery
Study: NCT02981940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Abemaciclib capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Abemaciclib capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Abemaciclib capsule

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery
Study: NCT01838538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC:paclitaxel + carboplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TC:paclitaxel + carboplatin
Study: NCT02215850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLC-0111
Study: NCT00584389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rimonabant
Description: 20mg/d (oral) once daily for 12 weeks

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Dietary intervention
Description: Dietary intervention to match weight loss in group 1. The energy prescription will be based on the estimate of the energy deficit estimated from the weight loss in group one. For example a weight loss of 5kg over 12 weeks equates to an approximate energy deficit of 30,000 kcal or a daily energy reduction of approximately 357 kcal. If this is achieved in group 1 the daily energy target for subjects in group 2 will be daily energy expenditure minus 357 kcal.For the subjects randomised to the dietary intervention group there will be a delay until group 1 subjects have completed the study.
Study: NCT03321721

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suture for wound repair
Description: Repair of wound with suture

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Suture for wound repair
Description: Repair of wound with suture
Study: NCT00863915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril10 mg Capsules, single dose
Description: A: Experimental Subjects received Purepac formulated products sprinkled on one tablespoonful of applesauce

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atlace® 10 mg capsules, single dose
Description: B: Active comparator Subjects received Monarch Pharmaceuticals Inc. formulated products sprinkled on one tablespoonful of applesauce